Takeda Reports FY2017 Full Year Results and Issues FY2018 Guidance

OSAKA, Japan–(BUSINESS WIRE)–May 14, 2018–Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +5.5% led by Takeda’s Growth Drivers Underlying Revenue grew +5.5%, with Takeda’s Growth Drivers (Gastroenterology, Oncology …
( read original story …)


Related Post

Earthquake standards are on shaky ground
views 194
In 1952, the government devised a map of Japan tha...
Nikkei edges down but mining shares soar on Japan-...
views 241
Japanese stocks barely moved on Tuesday ahead of a...
Japan’s prime minister heads to Russia for t...
views 34
TOKYO – Japan's Prime Minister Shinzo Abe is headi...
Moderate earthquake 5 mag, 92 km E of Nishinoomote...
views 122
A moderate earthquake with magnitude 5 (ml/mb) was...
Toshiba Mulls a Swiss IPO for Landis+Gyr by Septem...
views 202
Toshiba, slated for demotion to the second board o...
Tokyo 2020 Olympic Games costs double
views 232
The price tag on the 2020 Tokyo Olympic Games has ...
Japan and UK to expand joint military exercises
views 114
LONDON -- Japan and the U.K. have agreed to expand...
Japan is Back — Nikkei Hits 26-Year High, and Yet…...
views 116
Japanese stocks hit a 26-year high last week to tr...
UPDATE 1-Japan bank MUFG's profit down 2.6 pc...
views 200
TOKYO, May 15 Mitsubishi UFJ Financial Group (MUFG...
Japan auto association hopes free trade, low tarif...
views 72
But U.S. restrictions on vehicle and component imp...